{
    "nctId": "NCT04388384",
    "briefTitle": "Real-life Pan-HER-blockade With Neratinib",
    "officialTitle": "Neratinib in Patients With HER2+ Breast Cancer: a Multi-centric, Multi-national, Prospective, Longitudinal, Non-interventional Study in Germany, Austria and Switzerland",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Neoplasm",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 304,
    "primaryOutcomeMeasure": "Patient Compliance",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Written informed consent of the patient with regard to the pseudonymized documentation;\n* Legally capable female patient \u2265 18 years of age (no upper limit);\n* Decision was taken to treat the patient with neratinib in accordance with the current SmPC and by prescription; this decision was taken prior to and independent from the inclusion into the study;\n* Treatment with neratinib is planned to be started;\n* Hormone receptor (HR) positive, Human epidermal growth factor receptor 2 (HER2) overexpressing/amplified breast cancer stage I-III;\n* Completion of prior trastuzumab-based therapy less than 1 year ago;\n* No signs of relapse before initiation of neratinib treatment.\n\nExclusion Criteria:\n\n* Presence of any contraindication with regard to the neratinib treatment as specified in the corresponding Summary of Product Characteristics (SmPC);\n* Current or upcoming participation in an interventional clinical trial;\n* Prisoners or persons who are compulsorily detained (involuntarily incarcerated)",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}